RASAL2 and renal cell carcinoma: Based on the analyses of VHL gene mutation data in RCC patients from TCGA database, we found a slight significant difference in terms of RASAL2 mRNA expression between VHL wild-type and mutation patients, whereas there was no significant difference in different mutation subtypes or mutation sublocations (Figs. S4B, and 4C, D).